charted
Teva Earnings Miss by Record
The drugmaker’s bestseller was undercut by a rival
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd., the world’s largest maker of generic medicines, fell short of analysts’ estimates as a key competitor began selling a cheaper version of its bestselling drug Copaxone in the U.S. The 4.88 percent miss is the widest margin on record. The shares, which had dropped 61 percent this year in the U.S. throught Wednesday, fell in New York and in Israel.